148 related articles for article (PubMed ID: 16519007)
1. Assessment of GDNF in primate models of Parkinson's disease: comparison with human studies.
Eslamboli A
Rev Neurosci; 2005; 16(4):303-10. PubMed ID: 16519007
[TBL] [Abstract][Full Text] [Related]
2. Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.
Yasuhara T; Shingo T; Date I
Acta Med Okayama; 2007 Apr; 61(2):51-6. PubMed ID: 17471304
[TBL] [Abstract][Full Text] [Related]
3. GDNF delivery for Parkinson's disease.
Patel NK; Gill SS
Acta Neurochir Suppl; 2007; 97(Pt 2):135-54. PubMed ID: 17691299
[TBL] [Abstract][Full Text] [Related]
4. Increased brain bio-distribution and chemical stability and decreased immunogenicity of an engineered variant of GDNF.
Smith RC; O'Bryan LM; Mitchell PJ; Leung D; Ghanem M; Wilson JM; Hanson JC; Sossick S; Cooper J; Huang L; Merchant KM; Lu J; O'Neill MJ
Exp Neurol; 2015 May; 267():165-76. PubMed ID: 25771799
[TBL] [Abstract][Full Text] [Related]
5. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.
Decressac M; Ulusoy A; Mattsson B; Georgievska B; Romero-Ramos M; Kirik D; Björklund A
Brain; 2011 Aug; 134(Pt 8):2302-11. PubMed ID: 21712347
[TBL] [Abstract][Full Text] [Related]
6. Potential Therapeutic Approach using Aromatic l-amino Acid Decarboxylase and Glial-derived Neurotrophic Factor Therapy Targeting Putamen in Parkinson's Disease.
Tripathi RK; Goyal L; Singh S
Curr Gene Ther; 2024; 24(4):278-291. PubMed ID: 38310455
[TBL] [Abstract][Full Text] [Related]
7. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.
Björklund A; Kirik D; Rosenblad C; Georgievska B; Lundberg C; Mandel RJ
Brain Res; 2000 Dec; 886(1-2):82-98. PubMed ID: 11119690
[TBL] [Abstract][Full Text] [Related]
8. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
Whone AL; Boca M; Luz M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
J Parkinsons Dis; 2019; 9(2):301-313. PubMed ID: 30829619
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease.
Tereshchenko J; Maddalena A; Bähr M; Kügler S
Neurobiol Dis; 2014 May; 65():35-42. PubMed ID: 24440408
[TBL] [Abstract][Full Text] [Related]
10. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys.
Garbayo E; Ansorena E; Lana H; Carmona-Abellan MD; Marcilla I; Lanciego JL; Luquin MR; Blanco-Prieto MJ
Biomaterials; 2016 Dec; 110():11-23. PubMed ID: 27697668
[TBL] [Abstract][Full Text] [Related]
11. Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.
Migliore MM; Ortiz R; Dye S; Campbell RB; Amiji MM; Waszczak BL
Neuroscience; 2014 Aug; 274():11-23. PubMed ID: 24845869
[TBL] [Abstract][Full Text] [Related]
12. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
Connor B
Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):896-900. PubMed ID: 11703392
[TBL] [Abstract][Full Text] [Related]
13. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
J Neurosurg; 2007 Apr; 106(4):614-20. PubMed ID: 17432712
[TBL] [Abstract][Full Text] [Related]
14. Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?
Lindvall O; Wahlberg LU
Exp Neurol; 2008 Jan; 209(1):82-8. PubMed ID: 17963752
[TBL] [Abstract][Full Text] [Related]
15. GDNF-induced cerebellar toxicity: A brief review.
Luz M; Mohr E; Fibiger HC
Neurotoxicology; 2016 Jan; 52():46-56. PubMed ID: 26535469
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.
Whone A; Luz M; Boca M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
Brain; 2019 Mar; 142(3):512-525. PubMed ID: 30808022
[TBL] [Abstract][Full Text] [Related]
17. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.
Kordower JH; Emborg ME; Bloch J; Ma SY; Chu Y; Leventhal L; McBride J; Chen EY; Palfi S; Roitberg BZ; Brown WD; Holden JE; Pyzalski R; Taylor MD; Carvey P; Ling Z; Trono D; Hantraye P; Déglon N; Aebischer P
Science; 2000 Oct; 290(5492):767-73. PubMed ID: 11052933
[TBL] [Abstract][Full Text] [Related]
18. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
Garbayo E; Ansorena E; Blanco-Prieto MJ
Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
[TBL] [Abstract][Full Text] [Related]
19. Adeno-associated virus type 2 vector-mediated glial cell line-derived neurotrophic factor gene transfer induces neuroprotection and neuroregeneration in a ubiquitin-proteasome system impairment animal model of Parkinson's disease.
Du Y; Zhang X; Tao Q; Chen S; Le W
Neurodegener Dis; 2013; 11(3):113-28. PubMed ID: 22626907
[TBL] [Abstract][Full Text] [Related]
20. Intermittent convection-enhanced delivery of GDNF into rhesus monkey putamen: absence of local or cerebellar toxicity.
Luz M; Allen PC; Bringas J; Boiko C; Stockinger DE; Nikula KJ; Lewis O; Woolley M; Fibiger HC; Bankiewicz K; Mohr E
Arch Toxicol; 2018 Jul; 92(7):2353-2367. PubMed ID: 29785638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]